Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam-avibactam in neonates and infants with suspected or confirmed Gram-negative infection
2023-507757-15-01Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of aztreonam, avibactam and metronidazole in Gram-negative bacterial infection, bloodstream infection (BSI), Intra-abdominal infection (IAI) and 4 more (2 arms), sponsored by Pfizer. Primary endpoints: Pharmacokinetic parameters, Plasma concentrations of aztreonam and avibactam and 3 more. Planned start Apr 2025; status: authorised.
02
Drugs
aztreonamavibactammetronidazole
03
Conditions
Gram-negative bacterial infectionbloodstream infection (BSI)Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2023-507757-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507757-15-01.